Hemlock develops point-of-care tests for parasitic diseases targeting remote Indigenous communities and regional hospitals where lab infrastructure is limited. The Adelaide team has completed clinical validation studies with the University of Adelaide and is pursuing TGA approval for their lead diagnostic assay. Current focus is on diseases prevalent in Northern Territory and WA settings.